Skip to main content
. 2017 Dec 4;8(67):111836–111846. doi: 10.18632/oncotarget.22912

Figure 3. Survival and immune-infiltrate.

Figure 3

(A) 5-year overall survival according to CD8/Tia1 expression in localized osteosarcoma; (B) 5-year overall survival according to PD-L1 expression in patients with CD8+ localized osteosarcoma.